MEDPACTO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,010 KRW | -1.21% |
|
-3.53% | +24.45% |
| 2023 | MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd. | CI |
| 2023 | South Korean Shares Nearly Unchanged Ahead of US Inflation Data | MT |
ETFs positioned on MedPacto, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
MedPacto, Inc. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.
Calendar
08/11/2024
- Q3 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.45% | 221M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- A235980 Stock
- Funds and ETFs MedPacto, Inc.